Claims for Patent: 8,828,392

Summary for Patent: 8,828,392

Title:	Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
Abstract:	The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer; hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of an other chemotherapeutic agent, for example, an other chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN.RTM. (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Inventor(s):	Lichenstein; Henri (Branford, CT), Edwards; Nicholas (Abingdon, GB), Ritchie; James (Abingdon, GB), Petersen; Kamille Dumong (Copenhagen, DK), Plumb; Jane (Glasglow, GB)
Assignee:	TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:	12/093,069
Patent Claims:	1. A method of killing a B-cell lymphoma cell comprising contacting a B-cell lymphoma cell with, a first amount of a histone deacetylase inhibitor, and a second amount of an antibody against CD20, wherein the first and second amounts together comprise an amount effective to kill the B-cell lymphoma cell, and wherein the amount effective to kill the B-cell lymphoma cell has a synergistic effect compared to the effect of the first amount alone or the effect of the second amount alone; wherein the histone deacetylase inhibitor is a compound of formula: ##STR00009## or a pharmaceutically acceptable salt thereof; and wherein the antibody against CD20 is rituximab or an anti-CD20 antibody that binds to the same epitope on CD20 that is bound by rituximab. 2. The method according to claim 1, wherein the lymphoma is a Hodgkin's lymphoma. 3. The method according to claim 1, wherein the lymphoma is a non-Hodgkin's lymphoma.

Details for Patent 8,828,392

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-03-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-03-29
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2039-03-29